期刊文献+

非布司他治疗痛风伴高尿酸血症疗效观察 被引量:18

Efficacy of Febuxostat Tablets in the Treatment of Gout and Hyperuricemia
下载PDF
导出
摘要 目的分析非布司他治疗痛风伴高尿酸血症的临床效果。方法按照入院顺序将我院2011年5月~2015年11月收治的105例痛风伴高尿酸血症患者随机分为观察组(n=52)及对照组(n=53)。观察组采用非布司他治疗,对照组采用别嘌醇治疗,对比两组患者接受治疗后血尿酸的变化情况。结果观察组患者接受治疗之前的血尿酸值为(523.75±36.42)μmol/L,治疗之后的血尿酸值为(328.63±29.18)μmol/L。而对照组患者接受治疗之前的血尿酸值为(534.28±33.09)μmol/L,治疗之后的血尿酸值为(374.52±31.54)μmol/L。观察组患者的治疗情况优于对照组(P〈0.05)。结论采用非布司他治疗痛风伴高尿酸血症能够降低患者的血尿酸水平,改善患者的临床症状,提高患者的生活质量。 Objective To analyze the clinical effect of febuxostat in the treatment of gout and hyperuricemia. Methods According to the order of admission,105 cases of gout and hyperuricemia were randomly divided into observation group(n=52)and control group(n=53)in our hospital from May 2011 to November 2015. The observation group using the febuxostat treatment,control group was treated with allopurinol treatment,compared two groups of patients after treatment serum uric acid changes. Results In the observation group,the serum uric acid level was(523.75±36.42)mol/L before treatment,the serum uric acid value was(328.63±29.18)mol/L. While the control group received treatment before the blood uric acid value was(534.28±33.09)mol/L,after the treatment of blood uric acid value was(374.52±31.54)mol/L. The treatment of observation group was significantly better than the control group(P 〈 0.05). Conclusion The treatment of gout with hyperuricemia can significantly reduce the level of serum uric acid,improve the clinical symptoms of patients,improve the quality of life of patients.
作者 谷丽梅
出处 《中国卫生标准管理》 2016年第7期106-107,共2页 China Health Standard Management
关键词 非布司他 痛风伴高尿酸血症 疗效观察 Febuxostat tablets Gout and hyperuricemia Curative effect observation
  • 相关文献

参考文献5

二级参考文献50

  • 1Yokoi K,Adachi H,Hirai Y,et al.Plasma endothelin-1 level is a predictor of 10-year mortality in a general population:the Tanushimaru study[J].Circ J,2012,76(12):2779-2784.
  • 2Cappola TP,Kass DA,Nelson GS,et al.Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy[J].Circulation,2001,104(20):2407-2411.
  • 3Sui X,Church TS,Meriwether RA,et al.Uric acid and the development of metabolic syndrome in women and men[J].Metabolism,2008,57(6):845-852.
  • 4George J,Carr E,Davies J,et al.High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid[J].Circulation,2006,114(23):2508-2516.
  • 5Schumacher HR,Becker MA,Wortmann RL,et al.Effects of febuostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial[J].Arthritis Rheum,2008,59(11):1540-1548.
  • 6Van Beneden R,Gurne O,Selvais PL,et al.Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure:a 7-year follow-up study[J].Card Fail,2004,10(6):490-495.
  • 7Rudijanto A.The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J].Acta Med Indones,2007,39(2):86-93.
  • 8Terkeltauh R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [J]. Arthritis Res Ther, 2006, 8( Suppl 1) : S4.
  • 9Chao 1, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout [J]. CUff Rheumatol Rep, 2009,11 (2): 135-140.
  • 10Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout [J]. Cochrane Database Syst Rev, 2012, 14 (1):11.

共引文献150

同被引文献153

引证文献18

二级引证文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部